Extrawell Pharmaceutical Holdings Limited provided unaudited consolidated earnings guidance for the year ended 31 March 2023. For the year, Group expects to record a loss of about HKD 190 million as compared to a profit for the year ended 31 March 2022, which was primarily attributable to a non-cash item, resulted from a loss of about HKD 165 million arising from the fair value change of the Group's investments in convertible bonds, while a gain of about HKD 169 million due to the fair value change of the same non-cash item was incurred last year.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.037 HKD | -2.63% | -5.13% | +8.82% |
2023 | Extrawell Pharmaceutical Swings to Fiscal H1 Loss on Fair Value Losses | MT |
2023 | Extrawell Pharmaceutical Holdings Limited Reports Earnings Results for the Half Year Ended September 30, 2023 | CI |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+8.82% | 11.61M | |
+41.89% | 748B | |
+34.11% | 598B | |
-6.61% | 356B | |
+18.17% | 325B | |
+3.84% | 283B | |
+17.02% | 245B | |
+9.26% | 211B | |
-4.21% | 209B | |
+1.77% | 166B |
- Stock Market
- Equities
- 858 Stock
- News Extrawell Pharmaceutical Holdings Limited
- Extrawell Pharmaceutical Holdings Limited Provides Unaudited Consolidated Earnings Guidance for the Year Ended 31 March 2023